Abstract |
The acute and long-term effects of oral pergolide mesylate, a new potent, long-acting dopamine agonist, were investigated in 10 hyperprolactinaemic patients. After a single 50 micrograms dose of pergolide mesylate, serum prolactin concentrations fell steadily to reach a mean minimum value at 6 h of 20% of baseline values; this degree of suppression was maintained throughout the 24 h study period. In one patient serum prolactin was measured for 2 days after a single dose and remained suppressed for 45 h. There were no acute changes in the serum concentration of luteinising hormone, follicle-stimulating hormone and growth hormone. Preliminary evaluation of longer term treatment with pergolide indicates that this drug at a once-daily dose of 50-150 micrograms is a safe, well tolerated, and effective new treatment for hyperprolactinaemia.
|
Authors | S Franks, P M Horrocks, S S Lynch, W R Butt, D R London |
Journal | Lancet (London, England)
(Lancet)
Vol. 2
Issue 8248
Pg. 659-61
(Sep 26 1981)
ISSN: 0140-6736 [Print] England |
PMID | 6116045
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Ergolines
- Pergolide
- Bromocriptine
- Prolactin
- Luteinizing Hormone
- Follicle Stimulating Hormone
- Growth Hormone
|
Topics |
- Administration, Oral
- Adult
- Bromocriptine
(adverse effects)
- Depression, Chemical
- Ergolines
(administration & dosage, adverse effects, therapeutic use)
- Female
- Follicle Stimulating Hormone
(blood)
- Growth Hormone
(blood)
- Humans
- Luteinizing Hormone
(blood)
- Male
- Pergolide
- Prolactin
(blood)
- Time Factors
|